{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-24T04:03:01.977Z","profile":{"slug":"pemvidutide","name":"Pemvidutide","aliases":[],"category":"GLP-1/glucagon receptor agonist"},"synthesis":{"mechanism":"Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis and related metabolic outcomes. Liver histology, noninvasive markers, weight, and cardiovascular risk factors are distinct endpoints.","evidence":"WPF’s atlas includes reports and abstracts from the phase 2b IMPACT study and a meta-analysis of randomized trials. Conference abstracts and top-line reports can flag emerging results, but require comparison with complete methods and peer-reviewed outcome data before firm conclusions.","safety":"A change in a surrogate marker or exploratory analysis does not by itself establish clinical benefit, durability, or an approved indication.","observationalBoundary":"WPF's separate observational archive may include contributor reports concerning pemvidutide, investigated for liver-, weight-, and cardiovascular-risk-related outcomes. As with every entry in that archive, these de-identified reports can suggest questions but cannot establish causation, efficacy, comparative safety, or event frequency, and reports concerning different outcome domains should be interpreted separately.","openQuestions":"What do full controlled trial reports show for predefined liver outcomes and harms? How do noninvasive tests align with histology? Which effects persist beyond the reported follow-up?"},"completion":{"version":"wpf-profile-v1.1","verifiedSourceCount":5,"evidenceDepth":"limited_evidence","complete":false,"checks":[{"key":"overview","passed":true,"actual":256,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":285,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":140,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":420,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":183,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":5,"required":1,"severity":"blocking"},{"key":"evidence_depth_target","passed":false,"actual":5,"required":25,"severity":"warning"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["evidence_depth_target","reviewed_sources","claims"]},"chemistry":{"id":"fef3f313-8c7d-47f8-9e07-13cebda3960e","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","molecularFormula":null,"molecularWeight":null,"aminoAcidSequence":"His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Ala-Ala-Lys-Glu-Phe-Ile-Gln-Trp-Leu-Leu-Gln-Thr-NH2","smiles":null,"inchi":null,"inchikey":null,"structureImageUrl":null,"createdAt":"2026-09-23T02:36:54.177Z","updatedAt":"2026-09-23T02:36:54.177Z"},"evidence":[{"id":"4556b796-4ef4-4f22-9570-580d3e240157","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41879841/","evidenceTier":"insufficient","summary":"Content-verified record concerning Pemvidutide: \"Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.\" Abstract excerpt: Metabolic dysfunction-associated steatohepatitis (MASH) contributes substantially to liver and cardiometabolic disease. Pemvidutide, a dual GLP-1/glucagon receptor agonist, may provide combined hepatic and systemic benefits. We conducted a meta-analysis of randomized controlled trials comparing pemvidutide versus placebo in adults with MASLD/MASH. Data were pooled using random-effects models to es","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1007/s00210-026-05257-1","pubmedId":"41879841","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: systematic review or meta-analysis. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=120, totalMentions=4). Imported evidence lane: synthesis. Source provider: WPF seed. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"systematic_review_or_meta_analysis","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00210-026-05257-1","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.497Z","updatedAt":"2026-09-23T23:29:34.093Z"},{"id":"a6848a84-302a-4234-b094-1ff398ccbf53","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/39002641/","evidenceTier":"animal","summary":"Randomized study in MASLD; endpoint and follow-up require full-text appraisal.","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1016/j.jhep.2024.07.006","pubmedId":"39002641","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Upgraded from an entered/unverified draft to a content-verified citation. Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=87, totalMentions=7). Imported evidence lane: preclinical_animal. Source provider: WPF seed. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":"This publication addresses Pemvidutide in the specific setting identified in its title.","supportNature":"Screened source-level context; specific outcomes and evidence tier await appraisal.","qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.jhep.2024.07.006","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T02:13:10.585Z","updatedAt":"2026-09-23T23:29:34.093Z"},{"id":"a5e61daf-d194-4934-b54e-b20a1443d677","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41113119/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Pemvidutide: \"Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.\" Abstract excerpt: This was a double-blind 12-week extension of a randomized, placebo-controlled, 12-week trial of pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Completers of a double-blind trial of pemvidutide in MASLD, who were previously randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or ","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1016/j.jhepr.2025.101483","pubmedId":"41113119","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=96, totalMentions=9). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.jhepr.2025.101483","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.689Z","updatedAt":"2026-09-23T23:29:34.093Z"},{"id":"6fc8b854-309f-44f3-ad66-f3620f8044b4","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41237796/","evidenceTier":"animal","summary":"Content-verified record concerning Pemvidutide: \"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.\" Abstract excerpt: GLP-1-glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of this trial was to assess the effects of pemvidutide on MASH resolution and fibrosis improvement in patients with liver fibrosis stage F2 or F3 MASH at 24 weeks of treatment. IMPACT is an ongoing 48-week international, randomised, double-blind,","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1016/S0140-6736(25)02114-2","pubmedId":"41237796","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=46, totalMentions=13). Imported evidence lane: preclinical_animal. Source provider: WPF seed. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(25)02114-2","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.616Z","updatedAt":"2026-09-23T23:29:34.093Z"},{"id":"913d7425-6f7c-4e1a-a2e5-b4b0da980a40","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41352959/","evidenceTier":"insufficient","summary":"Content-verified record concerning Pemvidutide: \"The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.\" (identity confirmed; no abstract text available to excerpt.)","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1016/s0140-6736(25)02304-9","pubmedId":"41352959","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: Read directly: title and known trial identity confirm a primary pemvidutide phase 2b report; not yet MEDLINE-indexed.. Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(25)02304-9","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T23:11:35.223Z","updatedAt":"2026-09-23T23:29:34.093Z"}],"regulatory":[{"id":"e81499ee-f1da-4570-beaa-78087a433012","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","jurisdiction":"European Union — EMA","status":"not_approved","approvedIndication":null,"rationale":"No centrally authorized EMA medicine containing pemvidutide was identified in the EMA medicines database as of 2026-09-23. Pemvidutide remains investigational with no completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific.","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","dateChecked":"2026-09-23T00:00:00.000Z","reviewDueAt":"2026-12-22T00:00:00.000Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-23T02:42:18.950Z","updatedAt":"2026-09-23T23:29:34.166Z"},{"id":"368e5069-d525-46ce-bb1f-51374694020d","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","jurisdiction":"United States — FDA","status":"not_approved","approvedIndication":null,"rationale":"No FDA-approved product containing pemvidutide was identified in the FDA Drugs@FDA database as of 2026-09-23. Pemvidutide (ALT-801) remains an investigational compound in clinical development, with no completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific.","sourceTitle":"FDA Drugs@FDA database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","dateChecked":"2026-09-23T00:00:00.000Z","reviewDueAt":"2026-12-22T00:00:00.000Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-23T02:42:18.875Z","updatedAt":"2026-09-23T23:29:34.166Z"}],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}